Latest Edith Perez Stories
--- Significant Survival Benefit Observed in Pre-Specified Subgroups Including Patients with Brain Metastases and Patients with Baseline Liver Metastases --- SAN FRANCISCO, March
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer.
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.
ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin.
Results for testing breast tumors for HER2 proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed.
SAN MATEO, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Con-way Inc. (NYSE: CNW) announced that Edith R. Perez has been named to the Board of Directors.
Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care
- The parings of haberdine; also, any kind of fragments.